Bausch+Lomb has acquired an exclusive global license to a new...
Bausch+Lomb has acquired an exclusive global license to a new technology for the treatment of ocular redness, one of the most common ophtalmological conditions, affecting millions of people worldwide. Licensed from Eye Therapies, a biopharmaceutical company, and developed in collaboration with Ora, a private research organization, the technology employs a ...
To continue reading this article register now.
Already an Eyewear Intelligence subscriber? Sign in here.
Become a member today for full access from just €7,29 a week!
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.